IL315848A - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment - Google Patents

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment

Info

Publication number
IL315848A
IL315848A IL315848A IL31584824A IL315848A IL 315848 A IL315848 A IL 315848A IL 315848 A IL315848 A IL 315848A IL 31584824 A IL31584824 A IL 31584824A IL 315848 A IL315848 A IL 315848A
Authority
IL
Israel
Prior art keywords
egfr
cancer
treatment
combination
growth factor
Prior art date
Application number
IL315848A
Other languages
English (en)
Hebrew (he)
Inventor
Nicolas Floch
Matthew Joseph Martin
Paul David Smith
Ursula Grazini
Original Assignee
Astrazeneca Ab
Nicolas Floch
Matthew Joseph Martin
Paul David Smith
Ursula Grazini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Nicolas Floch, Matthew Joseph Martin, Paul David Smith, Ursula Grazini filed Critical Astrazeneca Ab
Publication of IL315848A publication Critical patent/IL315848A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315848A 2022-03-31 2023-03-30 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment IL315848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263325861P 2022-03-31 2022-03-31
PCT/EP2023/058261 WO2023187037A1 (en) 2022-03-31 2023-03-30 Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL315848A true IL315848A (en) 2024-11-01

Family

ID=86007676

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315848A IL315848A (en) 2022-03-31 2023-03-30 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment

Country Status (11)

Country Link
US (1) US20250205233A1 (enExample)
EP (1) EP4499102A1 (enExample)
JP (1) JP2025510910A (enExample)
KR (1) KR20240168418A (enExample)
CN (1) CN119278041A (enExample)
AU (1) AU2023246862A1 (enExample)
CA (1) CA3255389A1 (enExample)
IL (1) IL315848A (enExample)
MX (1) MX2024011959A (enExample)
TW (1) TW202408514A (enExample)
WO (1) WO2023187037A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20250538A (es) * 2023-05-26 2026-04-21 Astrazeneca Ab Composiciones farmacéuticas
KR20260024838A (ko) * 2024-08-14 2026-02-23 경희대학교 산학협력단 프로토사파닌 b 및 오시머티닙을 유효성분으로 포함하는 폐암의 예방 또는 치료용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
US8481503B2 (en) * 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
SG11201401953WA (en) 2011-10-31 2014-09-26 Betta Pharmaceuticals Co Ltd Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (zh) 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
WO2019126739A1 (en) * 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
WO2023035223A1 (zh) * 2021-09-10 2023-03-16 上海艾力斯医药科技股份有限公司 药物组合物及其用途

Also Published As

Publication number Publication date
JP2025510910A (ja) 2025-04-15
AU2023246862A1 (en) 2024-10-31
EP4499102A1 (en) 2025-02-05
CA3255389A1 (en) 2023-10-05
WO2023187037A1 (en) 2023-10-05
TW202408514A (zh) 2024-03-01
US20250205233A1 (en) 2025-06-26
MX2024011959A (es) 2024-12-06
KR20240168418A (ko) 2024-11-29
CN119278041A (zh) 2025-01-07

Similar Documents

Publication Publication Date Title
JOP20220182A1 (ar) مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
WO2010054285A3 (en) Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
MX2024011959A (es) Inhibidores de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr) junto con un inhibidor de la akt para el tratamiento del cáncer.
EP4051282A4 (en) METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS
MX2022014903A (es) Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
IL317733A (en) Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
EA202192552A1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого
EP4330224A4 (en) PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT
IL316829A (en) Menin-MLL inhibitors for cancer treatment
WO2004013091A3 (en) 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
IL321393A (en) CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency
MX2022008874A (es) Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
EP4097140A4 (en) USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCERS WITH NRG1 GENE FUSIONS
CA3263923A1 (en) PRMT5 inhibitors that cooperate with MTA for use in cancer treatment
IL320166A (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
PH12021552342A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40115952A (en) Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
HK40126841A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
IL318241A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
HK40126792A (en) Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
HK40085112A (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2008036254A3 (en) Autophagic compounds and tyrosine kinase inhibitors for treating cancer
MX2021013982A (es) Compuestos para inhibir la quinasa del egfr, metodos de preparacion y usos de los mismos.
CA3264745A1 (en) NEUROTROPHIC TYROSINE KINASE RECEPTOR (NTRK) INHIBITORS AND ASSOCIATED METHODS
IL315365A (en) Spleen tyrosine kinase inhibitor, composition and methods of use